Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/32265| Title: | Advances in the treatment of endometrial cancer. | Authors: | Oehler M.K.;Fung A.;Jobling T.W. | Institution: | (Oehler, Fung, Jobling) Dept. of Gynaecological Oncology, Monash Medical Centre, Moorabbin Campus, East Bentleigh, Vic. 3165, Australia | Issue Date: | 17-Oct-2012 | Copyright year: | 2005 | Publisher: | Royal Society of Medicine Press Ltd (P.O. Box 9002, London W1A 0ZA, United Kingdom) | Place of publication: | United Kingdom | Publication information: | Journal of the British Menopause Society. 11 (1) (pp 18-22), 2005. Date of Publication: March 2005. | Abstract: | Endometrial cancer (EC) most commonly affects postmenopausal women. It is curable if treated early, but tumours with adverse histopathological features or at an advanced stage are associated with a high mortality rate. These cancers require a complex therapeutic approach, consisting of surgery, radiotherapy, chemotherapy and/or hormonal therapy. As one of the leading causes of death from malignancy in women, EC has been subject to intense clinical investigation. This article examines recent advances in the surgical treatment of the disease, such as sentinel lymph node sampling and total laparoscopic hysterectomy, as well as topics such as conservative treatment of EC for fertility preservation. Furthermore, new agents for EC treatment are presented, for example inhibitors of the mTOR pathway and the angiogenesis-inhibitor VEGF-trap. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1258/1362180053654547 | PubMed URL: | 15814058 [http://www.ncbi.nlm.nih.gov/pubmed/?term=15814058] | ISSN: | 1362-1807 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/32265 | Type: | Review | Subjects: | drug tolerability *endometrium cancer/dt [Drug Therapy] *endometrium cancer/rt [Radiotherapy] *endometrium cancer/su [Surgery] *endometrium cancer/th [Therapy] histopathology human hyperthermic therapy fulvestrant/ct [Clinical Trial] laparoscopic surgery laparotomy meta analysis nonhuman postmenopause review salpingooophorectomy sentinel lymph node biopsy anastrozole/ct [Clinical Trial] anastrozole/dt [Drug Therapy] anastrozole/po [Oral Drug Administration] angiogenesis inhibitor/dt [Drug Therapy] angiogenesis inhibitor/pd [Pharmacology] antineoplastic agent/ae [Adverse Drug Reaction] antineoplastic agent/ct [Clinical Trial] antineoplastic agent/cb [Drug Combination] antineoplastic agent/cm [Drug Comparison] antineoplastic agent/dt [Drug Therapy] antineoplastic agent/pr [Pharmaceutics] antineoplastic agent/pd [Pharmacology] aromatase inhibitor/ct [Clinical Trial] aromatase inhibitor/dt [Drug Therapy] aromatase inhibitor/po [Oral Drug Administration] cisplatin/ct [Clinical Trial] cisplatin/cb [Drug Combination] cisplatin/cm [Drug Comparison] cisplatin/dt [Drug Therapy] doxorubicin/ae [Adverse Drug Reaction] doxorubicin/ct [Clinical Trial] doxorubicin/cb [Drug Combination] doxorubicin/cm [Drug Comparison] doxorubicin/dt [Drug Therapy] doxorubicin/pr [Pharmaceutics] epirubicin/ct [Clinical Trial] epirubicin/cb [Drug Combination] epirubicin/dt [Drug Therapy] everolimus/ct [Clinical Trial] everolimus/dt [Drug Therapy] everolimus/po [Oral Drug Administration] fluorouracil/ct [Clinical Trial] fluorouracil/cb [Drug Combination] fluorouracil/dt [Drug Therapy] gestagen/ct [Clinical Trial] gestagen/cb [Drug Combination] gestagen/dt [Drug Therapy] gestagen/po [Oral Drug Administration] gestagen/pa [Parenteral Drug Administration] gestagen/pr [Pharmaceutics] gonadorelin derivative/dt [Drug Therapy] letrozole/dt [Drug Therapy] liposome/pr [Pharmaceutics] mammalian target of rapamycin/ec [Endogenous Compound] medroxyprogesterone acetate/ct [Clinical Trial] medroxyprogesterone acetate/cb [Drug Combination] medroxyprogesterone acetate/dt [Drug Therapy] megestrol acetate/ct [Clinical Trial] megestrol acetate/dt [Drug Therapy] paclitaxel/ct [Clinical Trial] paclitaxel/cb [Drug Combination] paclitaxel/dt [Drug Therapy] rapamycin/pd [Pharmacology] tamoxifen/ct [Clinical Trial] tamoxifen/cb [Drug Combination] tamoxifen/dt [Drug Therapy] temsirolimus/ct [Clinical Trial] temsirolimus/dt [Drug Therapy] temsirolimus/pd [Pharmacology] trastuzumab/ct [Clinical Trial] trastuzumab/dt [Drug Therapy] trastuzumab/pd [Pharmacology] unclassified drug vasculotropin caelix vasculotropin trap/ct [Clinical Trial] vasculotropin trap/dt [Drug Therapy] vasculotropin trap/pd [Pharmacology] hysterectomy fulvestrant/dt [Drug Therapy] antineoplastic activity bone marrow toxicity/si [Side Effect] cancer chemotherapy cancer hormone therapy cancer mortality cancer radiotherapy cancer staging cancer survival cardiotoxicity/si [Side Effect] clinical trial conservative treatment drug delivery system drug efficacy drug formulation drug delivery system drug efficacy drug formulation drug tolerability *endometrium cancer / *drug therapy / *radiotherapy / *surgery / *therapy histopathology human hyperthermic therapy hysterectomy laparoscopic surgery laparotomy meta analysis nonhuman postmenopause review salpingooophorectomy sentinel lymph node biopsy cancer chemotherapy antineoplastic activity bone marrow toxicity / side effect cancer hormone therapy cancer mortality cancer radiotherapy cancer staging cancer survival cardiotoxicity / side effect clinical trial conservative treatment |
Type of Clinical Study or Trial: | Systematic review and/or meta-analysis |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.